临界可切除胰腺癌新辅助治疗的研究进展

Updates on neoadjuvant therapy in borderline resectable pancreatic cancer

临界可切除胰腺癌（BRPC）是介于可切除和不可切除胰腺癌之间的一种特殊类型,手术切除率低,术后复发率高.目前,对BRPC进行新辅助治疗使其转化为可切除的胰腺癌已成为胰腺癌领域的研究热点.新辅助治疗在显著提高BRPC的R0切除率及延长胰腺癌患者整体中位生存期中发挥了重要的作用.但至今未见其规范化的治疗方案出台.本文对BRPC新辅助治疗的研究进展做一综述.

Borderline resectable pancreatic cancer （BRPC）,characterized by low resectability rate and high postoperative recurrence rate,is a special kind of pancreatic cancer between resectable type and nonresectable one.Currently,the efficacy of neoadjuvant therapy for BRPC has become a hot topic in the field of pancreatic cancer.Although neoadjuvant therapy plays a critical role in obviously improving the R0 resectability rate and survival status of BRPC patients,the normalized therapeutic regimen has not been established.In this article,we overviewed the recent progress on the neoadjuvant therapy in treating BRPC.